One Peptide, Four Legal Lives: The Categories US Law Keeps Separate

Ask "is this peptide legal?" and you have already asked the wrong question, because a single peptide can live in four separate legal states at once, and each answers a different question. The same molecule may be an FDA-approved finished drug, a substance a pharmacy is allowed to compound under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, a chemical sold only for laboratory use, or a name parked on an FDA list while the agency decides what to do with it. Knowing which state a peptide occupies tells you very little about the other three.

Key points#

• Approval, compounding eligibility, research-only sale, and pending list status are four distinct designations, not four synonyms.
• A drug is approved as a specific finished product for specific uses, never as a raw ingredient.
• "For research use only" describes intended use, not a grade of quality or safety.
• Being removed from a "do not compound" list is not the same as being cleared to compound.
• Marketing language often borrows the authority of one state to describe a peptide sitting in another.

Why one label never covers the rest#

A useful comparison is the paperwork a person carries. A birth certificate, a driver's license, and a library card all belong to the same individual, yet each certifies a different thing, and holding one says nothing about the others. Peptide regulation works the same way. The four states below are not a ranking from least to most legitimate. They are four separate answers to four separate questions, and the whole point of the system is to keep them from being confused.

State one: an approved finished drug#

An FDA-approved peptide is a finished product that a manufacturer tested in clinical trials and that the agency reviewed for safety, effectiveness, manufacturing quality, and labeling. Semaglutide (sold as Ozempic, Wegovy, and Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) are approved peptide-based drugs, each cleared for defined uses at a defined dose in a defined formulation.

The key idea is that approval attaches to a product, not to a molecule floating free of context. A drug is approved as a particular finished item made a particular way, which is exactly why the same peptide can be lawful in one form and unlawful in another. The raw ingredient a compounder might purchase did not go through that review, so it does not carry that approval.

State two: a substance a pharmacy may compound#

Compounding means combining or altering ingredients to make a medication suited to a patient. US law sets up two compounding routes, and they are not interchangeable.

Section 503A covers traditional pharmacy compounding: usually patient-specific, prescription-driven, done at a state-licensed pharmacy. Section 503B covers "outsourcing facilities" that register with the FDA, follow current good manufacturing practice, and can make larger batches without a patient-specific prescription. Each route keeps its own list of bulk drug substances that may be used, and those lists answer to different statutory standards. A substance allowed on one route is not automatically allowed on the other.

The 503B route hinges on a "clinical need" finding. In a proposal announced on April 30, 2026, the FDA moved to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating that it had not identified a clinical need for outsourcing facilities to compound these drugs from bulk substance. The Federal Register notice published May 1, 2026, opened a public comment period, which the agency later extended in a separate notice. This is the cleanest illustration of why the states must stay separate: a peptide approved as a finished drug can, at the very same time, be proposed for removal from a compounding list. Approval and compounding eligibility answer different questions, and a proposal remains a proposal until the agency issues a final determination.

State three: a chemical labeled for the lab bench#

A large share of peptide material is sold as "for research use only," meaning it is meant for laboratory work rather than administration to people. Sections 503A and 503B govern drugs intended for administration to a human being, so material genuinely bound for in-vitro assays, instrument calibration, or preclinical animal studies falls outside those provisions.

Here is the caution that matters most. The research-only label describes intended use, not a safety grade. It is not a lower-key version of approval, and it comes with no assurance of the identity, purity, or sterility a medicine is held to. Diverting a research-labeled chemical toward human use does not carry over any of the protections that attach to an approved or properly compounded product. It walks away from them.

State four: a name on an FDA list awaiting a decision#

The fourth state is the one most often mistaken for the others. When no approved product covers a need, a bulk drug substance generally must appear on an FDA list to be eligible for compounding. While the agency evaluates nominated substances, it sorts many into an interim framework. As the FDA's 503A guidance explains, Category 1 substances are those nominated with enough information to evaluate and against which the agency does not intend to act while review continues, provided the guidance conditions are met. Category 2 substances are those the agency has flagged as raising significant safety concerns, which makes them ineligible for the Category 1 policy.

In 2026 the FDA removed a set of peptides from Category 2 and announced Pharmacy Compounding Advisory Committee (PCAC) meetings, held in July 2026, to consider recommending that certain peptide bulk substances be added to the 503A list. Read that sequence carefully. Coming off a "do not compound" safety-risk category is not approval, is not placement on the permitted Category 1 list, and is not permission to compound. The PCAC is an advisory body, and its recommendations are non-binding. Adding a substance to the 503A bulks list takes notice-and-comment rulemaking, a formal process that would follow any recommendation. A committee agenda is a plan to deliberate, and nothing more.

How the marketing blurs the lines#

These distinctions get collapsed on purpose. Phrases like "FDA-registered facility," "clinical-grade," and "under FDA review" lift the authority of one state to dress up a peptide sitting in another. A registered outsourcing facility is not an approved drug. A substance under evaluation is not an approved substance. A research chemical is not a medicine. The habit worth building is to ask which specific state applies to this specific molecule in this specific form, and to refuse to let a good-sounding phrase from one category stand in for the others.

The practical value of keeping the four states apart is not legal trivia. Each state represents a different amount of evidence that a given peptide, in a given form, is what it claims to be and does what is claimed. Blur the categories and you discard that evidence, which is exactly what the categories exist to protect.